Silverfin false false 30/09/2024 15/09/2023 30/09/2024 A Hersham 15/09/2023 Dr L Osherovich 15/09/2023 13 June 2025 no description of principal activity 15140523 2024-09-30 15140523 bus:Director1 2024-09-30 15140523 bus:Director2 2024-09-30 15140523 core:CurrentFinancialInstruments 2024-09-30 15140523 core:ShareCapital 2024-09-30 15140523 core:FurtherSpecificReserve2ComponentTotalEquity 2024-09-30 15140523 core:RetainedEarningsAccumulatedLosses 2024-09-30 15140523 core:OtherResidualIntangibleAssets 2023-09-14 15140523 2023-09-14 15140523 core:OtherResidualIntangibleAssets 2024-09-30 15140523 2023-09-15 2024-09-30 15140523 bus:FilletedAccounts 2023-09-15 2024-09-30 15140523 bus:SmallEntities 2023-09-15 2024-09-30 15140523 bus:AuditExemptWithAccountantsReport 2023-09-15 2024-09-30 15140523 bus:PrivateLimitedCompanyLtd 2023-09-15 2024-09-30 15140523 bus:Director1 2023-09-15 2024-09-30 15140523 bus:Director2 2023-09-15 2024-09-30 15140523 core:OtherResidualIntangibleAssets 2023-09-15 2024-09-30 15140523 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-09-15 2024-09-30 15140523 core:OtherResidualIntangibleAssets 1 2023-09-15 2024-09-30 15140523 1 2023-09-15 2024-09-30 iso4217:GBP xbrli:pure

Company No: 15140523 (England and Wales)

NONSENSE THERAPEUTICS LTD

Unaudited Financial Statements
For the financial period from 15 September 2023 to 30 September 2024
Pages for filing with the registrar

NONSENSE THERAPEUTICS LTD

Unaudited Financial Statements

For the financial period from 15 September 2023 to 30 September 2024

Contents

NONSENSE THERAPEUTICS LTD

COMPANY INFORMATION

For the financial period from 15 September 2023 to 30 September 2024
NONSENSE THERAPEUTICS LTD

COMPANY INFORMATION (continued)

For the financial period from 15 September 2023 to 30 September 2024
DIRECTORS A Hersham (Appointed 15 September 2023)
Dr L Osherovich (Appointed 15 September 2023)
REGISTERED OFFICE 25 Randolph Crescent
London
W9 1DP
United Kingdom
COMPANY NUMBER 15140523 (England and Wales)
ACCOUNTANT Gravita Essex Limited
Treviot House
186-192 High Road
Ilford
Essex
IG1 1LR
United Kingdom
NONSENSE THERAPEUTICS LTD

BALANCE SHEET

As at 30 September 2024
NONSENSE THERAPEUTICS LTD

BALANCE SHEET (continued)

As at 30 September 2024
Note 30.09.2024
£
Fixed assets
Intangible assets 3 70,293
70,293
Current assets
Cash at bank and in hand 120,272
120,272
Creditors: amounts falling due within one year 4 ( 1,680)
Net current assets 118,592
Total assets less current liabilities 188,885
Net assets 188,885
Capital and reserves
Called-up share capital 2
Equity reserve 200,000
Profit and loss account ( 11,117 )
Total shareholders' funds 188,885

For the financial period ending 30 September 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Nonsense Therapeutics Ltd (registered number: 15140523) were approved and authorised for issue by the Board of Directors on 13 June 2025. They were signed on its behalf by:

A Hersham
Director
NONSENSE THERAPEUTICS LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 15 September 2023 to 30 September 2024
NONSENSE THERAPEUTICS LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 15 September 2023 to 30 September 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.

General information and basis of accounting

Nonsense Therapeutics Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 25 Randolph Crescent, London, W9 1DP, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Other intangible assets 25 % reducing balance
Research and development

Research expenditure is written off as incurred. Development expenditure is also written off, except where the directors are satisfied as to the technical, commercial and financial viability of individual projects. In such cases, the identifiable expenditure is capitalised as an intangible asset and amortised over the period during which the Company is expected to benefit. This period is between three and five years. Provision is made for any impairment.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

Period from
15.09.2023 to
30.09.2024
Number
Monthly average number of persons employed by the Company during the period, including directors 2

3. Intangible assets

Other intangible assets Total
£ £
Cost
At 15 September 2023 0 0
Additions 78,467 78,467
At 30 September 2024 78,467 78,467
Accumulated amortisation
At 15 September 2023 0 0
Charge for the financial period 8,174 8,174
0 0
At 30 September 2024 8,174 8,174
Net book value
At 30 September 2024 70,293 70,293

4. Creditors: amounts falling due within one year

30.09.2024
£
Other creditors 1,680